Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Xponance Inc.

Xponance Inc. cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 37.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,384 shares of the medical research company's stock after selling 2,634 shares during the period. Xponance Inc.'s holdings in Charles River Laboratories International were worth $660,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRL. Cibc World Markets Corp increased its holdings in shares of Charles River Laboratories International by 16.1% during the 4th quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company's stock valued at $1,493,000 after acquiring an additional 1,124 shares during the last quarter. Royal London Asset Management Ltd. lifted its position in shares of Charles River Laboratories International by 6.4% during the 4th quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company's stock worth $3,032,000 after buying an additional 991 shares during the period. Quantbot Technologies LP lifted its position in shares of Charles River Laboratories International by 13.8% during the 4th quarter. Quantbot Technologies LP now owns 9,300 shares of the medical research company's stock worth $1,717,000 after buying an additional 1,131 shares during the period. American Century Companies Inc. raised its position in Charles River Laboratories International by 5.6% in the 4th quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company's stock valued at $551,000 after purchasing an additional 157 shares during the last quarter. Finally, Sei Investments Co. raised its position in Charles River Laboratories International by 6.1% in the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company's stock valued at $124,394,000 after purchasing an additional 38,827 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Mizuho cut their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Finally, Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $174.54.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $4.78 during trading hours on Monday, reaching $149.70. 1,054,505 shares of the company were exchanged, compared to its average volume of 1,038,015. The company has a market capitalization of $7.35 billion, a P/E ratio of -230.31, a P/E/G ratio of 5.23 and a beta of 1.49. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The business has a 50 day moving average of $147.42 and a 200 day moving average of $150.35.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period in the prior year, the company earned $2.27 EPS. Charles River Laboratories International's revenue was down 2.7% compared to the same quarter last year. Research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).